Get the Stockscreener App
36.75
11.76%
-4.90
Pre-market:
36.85
0.10
+0.27%
Viking Therapeutics Inc stock is traded at $36.75, with a volume of 28.72M.
It is down -11.76% in the last 24 hours and up +10.59% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$41.65
Open:
$36.025
24h Volume:
28.72M
Relative Volume:
8.31
Market Cap:
$4.29B
Revenue:
-
Net Income/Loss:
$-472.34M
P/E Ratio:
-8.8642
EPS:
-4.1459
Net Cash Flow:
$-340.33M
1W Performance:
+25.17%
1M Performance:
+10.59%
6M Performance:
+14.24%
1Y Performance:
+38.00%
1-Day Range:
$35.11
$37.22
1-Week Range:
$28.40
$43.10
52-Week Range:
$24.88
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
36.75 | 4.29B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits
Viking Therapeutics (VKTX) Stock Looks Fully Priced Despite Its Huge Five Year Run - simplywall.st
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - finance.yahoo.com
Viking Therapeutics Plunges After Upsized $500 Million Financing Prices at 16% Discount - finance.biggo.com
One investor reportedly took a third of Viking’s share sale - Yahoo Finance Australia
Viking Therapeutics raises USD 500m to advance VK2735 obesity program - allsci.com
Latham Advises on Viking Therapeutics Upsized Offering of Common Stock and Convertible Senior Notes - Latham & Watkins LLP
Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race - TipRanks
Here's Why Viking Therapeutics Shares Slumped Today - The Motley Fool
Top Biotech Stocks To Keep An Eye OnSeptember 24th - MarketBeat
Why Is Viking Therapeutics Stock Trading Down Thursday? - Benzinga
Here's Why Viking Therapeutics Shares Slumped Today - The Motley Fool
Viking Therapeutics drops 15% after $500M stock offering; Jaguar Health falls 25% without news. - Pluang
Viking Therapeutics Sinks 12% on “Upsized” $500 Million Raise - finance.yahoo.com
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25% - AOL.ca
Biggest stock movers Thursday: P, VKTX, MGM, BE, and more - Seeking Alpha
Viking Therapeutics Prices Upsized Stock and Convertible Notes Offering at Discount - Intellectia AI
VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff - Yahoo Finance
What Did Viking Therapeutics (NASDAQ:VKTX) Maintenance Data Show for VK2735? - Kalkine Media
Viking Therapeutics Prices Upsized $500 Million Stock, Convertible Notes Offering - marketscreener.com
VKTX Stock Offering Raised to $225M with Morgan Stanley and JPMo - GuruFocus
Why is Viking Therapeutics stock tumbling today? By Investing.com - Investing.com Canada
Stitch Fix Posts Mixed Q4 Results, Joins Viking Therapeutics And Other Big Stocks Moving Lower In Thursda - Benzinga
Why is Viking Therapeutics stock tumbling today? - Investing.com
Viking Therapeutics raises $500M in upsized stock and notes offering - Dealroom
Viking Therapeutics prices $500M stock and debt offering - Investing.com
Viking Therapeutics prices $275M stock and conv... - Pluang
Viking Therapeutics prices $500M stock and debt offering By Investing.com - Investing.com Nigeria
Viking Therapeutics prices upsized $500M offering of common stock and convertible senior notes - TradingView
Viking Therapeutics Prices Upsized $500 Million Offering Of Common Stock And Convertible Senior Notes - TradingView
Viking Therapeutics, Inc. (VKTX) Prices Upsized $500M Stock and 2.00% Convertible Notes - TradingView
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks - Yahoo Finance
Positive VK2735 Clinical Data: Can Viking Therapeutics Displace Eli Lilly and Novo Nordisk? - NAI500
Is Viking Therapeutics (VKTX) Fully Valued On Its Positive VK2735 Trial Update? - simplywall.st
Viking Therapeutics Plans $400 Million Public Offerings - Intellectia AI
VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesday’s Rally - finance.yahoo.com
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 DiabetesSlideshow (NASDAQ:VKTX) 2026-09-22 - Seeking Alpha
Form 424B5 Viking Therapeutics Inc For: 23 September By Investing.com - Investing.com Canada
Viking Therapeutics (VKTX) Plans $400M Capital Raise Amid Mixed Market Signals - GuruFocus
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - finance.yahoo.com
Viking Therapeutics (VKTX) Plans $400M Capital Raise via Stock a - GuruFocus
Viking Therapeutics Announces Proposed Offerings Of Common Stock And Convertible Senior Notes - TradingView
Neither offering depends on the other: Viking Therapeutics (VKTX) offers notes and shares separately. - Stock Titan
Viking Therapeutics plans $400 million capital raise - Investing.com
Viking Therapeutics Stock Drops In After Hours on Proposed Public Offerings - Benzinga
Viking Therapeutics files plans for $400M in combined offerings of common stock, convertible notes - TradingView
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days - TradingView
Viking Therapeutics plans $400 million capital raise By Investing.com - Investing.com Nigeria
Viking Therapeutics stock falls on proposed equity offering - Investing.com
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):